↓ Skip to main content

Drug and Exercise Treatment of Alzheimer Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Effects on Cognition in Randomized Controlled Trials

Overview of attention for article published in American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry, July 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (88th percentile)
  • High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

news
1 news outlet
policy
1 policy source
twitter
5 X users
facebook
2 Facebook pages

Citations

dimensions_citation
164 Dimensions

Readers on

mendeley
383 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Drug and Exercise Treatment of Alzheimer Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Effects on Cognition in Randomized Controlled Trials
Published in
American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry, July 2015
DOI 10.1016/j.jagp.2015.07.007
Pubmed ID
Authors

Andreas Ströhle, Dietlinde K. Schmidt, Florian Schultz, Nina Fricke, Theresa Staden, Rainer Hellweg, Josef Priller, Michael A. Rapp, Nina Rieckmann

Abstract

Demographic changes are increasing the pressure to improve therapeutic strategies against cognitive decline in Alzheimer disease (AD) and mild cognitive impairment (MCI). Besides drug treatment, physical activity seems to be a promising intervention target as epidemiological and clinical studies suggest beneficial effects of exercise training on cognition. Using comparable inclusion and exclusion criteria, we analyzed the efficacy of drug therapy (cholinesterase inhibitors, memantine, and Ginkgo biloba) and exercise interventions for improving cognition in AD and MCI populations. We searched The Cochrane Library, EBSCO, OVID, Web of Science, and U.S Food and Drug Administration data from inception through October 30, 2013. Randomized controlled trials in which at least one treatment arm consisted of an exercise or a pharmacological intervention for AD or MCI patients, and which had either a non-exposed control condition or a control condition that received another intervention. Treatment discontinuation rates and Standardized Mean Change score using Raw score standardization (SMCR) of cognitive performance were calculated. Discontinuation rates varied substantially and ranged between 0% and 49% with a median of 18%. Significantly increased discontinuation rates were found for galantamine and rivastigmine as compared to placebo in AD studies. Drug treatments resulted in a small pooled effect on cognition (SMCR: 0.23, 95% CI: 0.20 to 0.25) in AD studies (N = 45, 18,434 patients) and no effect in any of the MCI studies (N = 5, 3,693 patients; SMCR: 0.03, 95% CI: 0.00 to 0.005). Exercise interventions had a moderate to strong pooled effect size (SMCR: 0.83, 95% CI: 0.59 to 1.07) in AD studies (N = 4, 119 patients), and a small effect size (SMCR: 0.20, 95% CI: 0.11 to 0.28) in MCI (N = 6, 443 patients). Drug treatments have a small but significant impact on cognitive functioning in AD and exercise has the potential to improve cognition in AD and MCI. Head-to-head trials with sufficient statistical power are necessary to directly compare efficacy, safety, and acceptability. Combining these two approaches might further increase the efficacy of each individual intervention. PROSPERO (2013:CRD42013003910).

X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 383 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
United States 1 <1%
Germany 1 <1%
Unknown 380 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 57 15%
Researcher 40 10%
Student > Ph. D. Student 39 10%
Student > Bachelor 37 10%
Student > Doctoral Student 22 6%
Other 77 20%
Unknown 111 29%
Readers by discipline Count As %
Medicine and Dentistry 64 17%
Psychology 43 11%
Nursing and Health Professions 38 10%
Neuroscience 31 8%
Sports and Recreations 19 5%
Other 63 16%
Unknown 125 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 September 2018.
All research outputs
#2,450,253
of 25,373,627 outputs
Outputs from American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry
#311
of 2,376 outputs
Outputs of similar age
#30,519
of 275,677 outputs
Outputs of similar age from American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry
#4
of 23 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,376 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.2. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 275,677 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.